These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 22168786

  • 1. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
    Henk HJ, Kaura S.
    J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
    Henk HJ, Kaura S, Teitelbaum A.
    J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
    Henk H, Teitelbaum A, Kaura S.
    Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
    [Abstract] [Full Text] [Related]

  • 6. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [Abstract] [Full Text] [Related]

  • 7. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V.
    Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A, Zheng M, Seaman J.
    Cancer; 2003 Sep 01; 98(5):962-9. PubMed ID: 12942563
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL.
    J Exp Clin Cancer Res; 2007 Sep 01; 26(3):307-12. PubMed ID: 17987788
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
    Saad F, Eastham J.
    Urology; 2010 Nov 01; 76(5):1175-81. PubMed ID: 21056263
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G.
    Oncology; 2004 Nov 01; 67(5-6):390-6. PubMed ID: 15713995
    [Abstract] [Full Text] [Related]

  • 19. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F, Chen YM, Gleason DM, Chin J.
    Clin Genitourin Cancer; 2007 Sep 01; 5(6):390-6. PubMed ID: 17956712
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.